In this article, we take a look at the 12 Best 52-Week High Stocks to Buy Right Now.
All three major US indices are poised to end the year near record highs in what is turning out to be a blockbuster year for stocks. Investors moving past concerns about the state of the economy amid tariffs and the trade war, exacerbated by monetary policy uncertainties, have seen equities rally to record highs.
The US Federal Reserve, embarking on an interest rate-cutting spree, has emerged as an essential catalyst, supporting equities. The easier monetary policy, at a time when sky-high valuations are arousing concerns, is also supporting bulls in the market.
“The Federal Reserve is cutting interest rates during a time when stocks are at record highs and the economy is still growing. This dynamic is bullish for stocks. Big tech stocks tend to outperform during lower interest-rate environments, and financials may see a boost from additional M&A and mortgage activity that may come about from lower rates,” said Robert Schein at Blanke Schein Wealth. Management.
With markets at all-time highs, there is growing concern of a potential bubble amid swollen valuations. Nevertheless, it’s becoming increasingly clear that solid financial results and a resilient US economy will support the elevated valuations.
“Investors have happily bought every dip, largely thanks to AI-driven enthusiasm and consistently strong results from big tech,” said Fawad Razaqzada at City Index and Forex.com. “The concern is that if tech momentum cools, the rest of the market may struggle to justify current valuations.”
Likewise, Ulrike Hoffmann-Burchardi at UBS Global Wealth Management expects lower interest rates, robust earnings growth, and AI tailwinds to offer much-needed support for global equities heading into year-end. With that in mind, let’s take a look at some of the Best 52-Week High Stocks to Buy Right Now.
Our Methodology
To compile our list of the 12 Best 52‑Week High Stocks to Buy Right Now, we used the Finviz stock screener to identify companies trading within 0%–10% of their 52‑week highs and showing year‑to‑date gains of more than 30%. These stocks are also favored by elite hedge funds and offer upside potential of over 20%. We then ranked them in ascending order based on the number of hedge funds holding positions as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best 52-Week High Stocks to Buy Right Now
12. Copa Holdings, S.A. (NYSE:CPA)
52 Week Range: $82.54 – $130.00
Current Share Price as of December 4: $118.24
Year to date Gain: 39.81%
Stock Upside Potential: 33.53%
Number of Hedge Fund Holders: 21
Copa Holdings, S.A. (NYSE:CPA) is one of the best 52-week high stocks to buy right now. Copa Holdings, S.A. (NYSE:CPA) has a strong Buy consensus rating from 5 Wall Street analysts, including 5 Buy ratings. The average price target on the stock is $161, implying 33.53% upside potential from the current level of $120.57 a share.
The positive stance on Wall Street coincides with the company’s delivery of another strong quarter on November 20, affirming the strength of its business model and competitive advantage in the Latin American aviation market. Disciplined cost management and healthy demand across networks also helped the company achieve industry-leading operating and net margins of 23.2% and 19%.
Operating revenues increased 6.8% in the third quarter to $913.1 million, attributed to 5.8% capacity growth. Passenger revenue was up 5.2% and cargo and mail revenue increased 21.4%. Earnings per share came in at $4.20, compared to the $4.04 forecast.
Meanwhile, on November 24, Barclay’s analyst Pablo Monsivais reiterated a Buy rating on the stock and set a $150 price target.
Copa Holdings, S.A. (NYSE:CPA) is a Panamanian company that provides passenger and cargo air transportation services throughout the Americas through its operating subsidiaries, Copa Airlines, Copa Airlines Colombia, and Wingo.
11. Immunocore Holdings plc (NASDAQ:IMCR)
52 Week Range: $23.15 – $40.71
Current Share Price as of December 4: $40.70
Year to date Gain: 43.84%
Stock Upside Potential: 62.25%
Number of Hedge Fund Holders: 25
Immunocore Holdings PLC (NASDAQ:IMCR) is one of the best 52-week high stocks to buy right now. Immunocore Holdings PLC (NASDAQ:IMCR) commands a consensus Moderate Buy rating from 9 Wall Street analysts, comprising 6 Buy and 3 Hold ratings. The average price target on the stock is $65.25, implying 62.25% upside potential.
On November 21, H.C. Wainwright’s Patrick Trucchio reaffirmed a Buy rating on Immunocore Holdings with a $100 price target, following TD Cowen’s Tyler Van Buren, who also issued a Buy on November 13.
Just days earlier, on November 19 at the Jefferies London Healthcare Conference 2025, Immunocore Holdings showcased strategic advancements that affirmed significant pipeline development and strong commercial performance. It has made significant progress on KIMMTRAK development, currently in Phase 3 trials in cutaneous melanoma.
The company is working on PRAME Bispecific, currently in Phase 3 trials as a potential treatment option for multiple cancers, with data expected in the first half of next year. In addition, it is pursuing cures for HIV and HBV. The pipeline development is supported by a robust cash position of about $892 million as of the end of the third quarter.
Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company that develops TCR bispecific immunotherapies to treat cancer, infectious diseases, and autoimmune conditions. Using its proprietary ImmTAX technology, the company designs therapies that harness the immune system by either activating it to destroy diseased cells or dampening it to reduce autoimmune responses.
10. Apogee Therapeutics Inc. (NASDAQ:APGE)
52 Week Range: $26.20 – $77.00
Current Share Price as of December 4: $75.43
Year to date Gain: 60.13%
Stock Upside Potential: 27.43%
Number of Hedge Fund Holders: 30
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best 52-week high stocks to buy right now. On December 3, TD Cowen’s Tyler Van Buren reiterated a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE). Earlier, on November 13, Canaccord Genuity’s Edward Nash reiterated a Buy rating on Apogee Therapeutics with a $89 price target, citing its strong financial position, cash reserves from a recent equity raise, and a promising pipeline. Key data readouts in 2026—including asthma and atopic dermatitis trials, could bolster its market standing, while the potential dosing advantage of APG777 over Dupixent adds to the positive outlook.
On November 10, Apogee Therapeutics reported that its antibody APG333 showed a 55‑day half‑life in Phase 1 trials, supporting potential quarterly or semi‑annual dosing. Clinical trials have shown that APG333 can suppress key biomarkers for up to six months on a single dose. It stands out in its ability to target thymic stromal lymphopoietin. In trials, the drug was well-tolerated with mild side effects.
The positive results affirm the company’s prospects in delivering durable activity, which may enable less frequent dosing compared to available agents.
“The extended PK and favorable tolerability profile of APG333 underscores Apogee’s potential to advance a quarterly or better dosing combination of APG777 and APG333, designed to address key drivers of respiratory diseases more broadly than a monotherapy,” said Michael Henderson, M.D., Chief Executive Officer of Apogee.
Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company that develops novel biologic therapies for inflammatory and immunological diseases. The company focuses on conditions such as atopic dermatitis, asthma, and COPD by advancing antibody-based drugs to improve efficacy and enable more convenient dosing.
9. Orla Mining Ltd. (NYSE:ORLA)
52 Week Range: $4.90 – $14.36
Current Share Price as of December 4: $12.86
Year to date Gain: 129.25%
Stock Upside Potential: 31.40%
Number of Hedge Fund Holders: 33
Orla Mining Ltd (NYSE:ORLA) is one of the best 52-week high stocks to buy right now. Orla Mining Ltd (NYSE:ORLA) commands a strong Buy rating from 6 Wall Street analysts. The average price target for the stock is $17.54, implying 31.40% upside from $13.35 a share.
On November 11, Chief Executive Officer Jason Simpson confirmed that the company had a strong third quarter, achieving a record free cash flow of $93 million. The bolstered balance sheet positions the company to self-finance the next stage of growth at the South Railroad project. Gold production in the quarter rose to 79,645 ounces.
Likewise, the company sold 78,857 ounces of gold and generated $257 million in revenue. Its net income totaled $49.3 million or $0.15 a share. Adjusted earnings totaled $73 million or $0.22 a share. Following the strong third-quarter results, BMO Capital analyst Andrew Mikitchook reiterated a Buy rating on the stock. Stifel Nicolaus analyst Ingrid Rico also maintains a Buy rating on the stock.
Orla Mining Ltd. (NYSE:ORLA) acquires, develops, and operates mineral properties, with a focus on gold and silver. It owns and operates the Camino Rojo gold and silver mine in Mexico, is developing the South Railroad project in Nevada, and recently acquired the Musselwhite gold mine in Ontario, Canada.
8. Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
52 Week Range: $26.70 – $271.94
Current Share Price as of December 4: $266.54
Year to date Gain: 134.10%
Stock Upside Potential: 75.71%
Number of Hedge Fund Holders: 33
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best 52-week high stocks to buy right now. Piper Sandler on December 5 reaffirmed its Overweight rating and $450 target on Praxis Precision Medicines (NASDAQ:PRAX) after two key regulatory wins.
The company’s pre-NDA meeting with the FDA confirmed its ulixacaltamide data package for Essential Tremor is on track for an NDA filing in early 2026. Analysts also highlighted strong interim results from the Phase 2/3 EMBOLD trial of relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathy, which was stopped early because it met efficacy goals.
A day earlier on December 4, H.C. Wainwright’s Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines with a $258 price target, citing the strength of its ESSENTIAL3 program for ulixacaltamide, supported by sensitivity analyses, expert validation, and FDA precedent review. His confidence was echoed by BTIG, which on December 2 initiated coverage with a Buy and a higher $424 target, underscoring optimism around the company’s pipeline and regulatory outlook.
On November 24, Praxis Precision received a Buy rating from TD Cowen, which also reiterated a $251 price target. The research firm’s positive stance is in response to positive topline results for ulixacaltamide (ulixa), Praxis’s treatment for essential tremor (ET).
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a biopharmaceutical company that develops therapies for neurological disorders, leveraging genetic insights to create targeted treatments for complex brain disorders such as epilepsy, movement disorders, and psychiatric conditions.
7. Disc Medicine, Inc. (NASDAQ:IRON)
52 Week Range: $30.82 – $97.11
Current Share Price as of December 4: $94.23
Year to date Gain: 50.12%
Stock Upside Potential: 24.39%
Number of Hedge Fund Holders: 34
Disc Medicine, Inc. (NASDAQ:IRON) is one of the best 52-week high stocks to buy right now. On November 20, analysts at Jefferies reiterated a Buy rating on the stock with a $127 price target. The research firm has echoed the company’s strong performance and continued momentum in 2026. It expects the momentum to be driven by the bitopertin approval as a treatment option for erythropoietic protoporphyria (EPP) and its potential launch early next year.
The company is staring at a tremendous opportunity following the Confirmed Pediatric Investigation Plan Verification (CNPV), which underscores unmet need around erythropoietic protoporphyria (EPP). Upcoming Phase 2 interim data for DISC-0974 in anemia myelofibrosis (MF) is also a potential catalyst.
Meanwhile, TD Cowen analyst Tara Bancroft reiterated a Buy rating on the stock on November 14, impressed by the promising outlook for bitopertin, a first-in-class treatment for erythropoietic protoporphyria (EPP). The drug is poised to capture significant market potential valued at $700 million.
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes new treatments for serious hematologic diseases, such as those affecting red blood cells and iron metabolism. They focus on building a pipeline of therapies that target fundamental biological pathways, including heme biosynthesis and iron homeostasis, to help patients with conditions like erythropoietic protoporphyria (EPP).
6. CG Oncology, Inc. (NASDAQ:CGON)
52 Week Range: $14.80 – $46.01
Current Share Price as of December 4: $43.83
Year to date Gain: 54.78%
Stock Upside Potential: 64.49%
Number of Hedge Fund Holders: 34
CG Oncology Inc. (NASDAQ:CGON) is one of the best 52-week high stocks to buy right now. On November 24, analysts at Truist Securities initiated coverage of CG Oncology Inc. (NASDAQ:CGON) with a Buy rating and a $62 price target. The positive stance comes as the research firm remains optimistic about the company’s Biologics License Application for its lead product Creto. While the application began in the fourth quarter, there is a higher prospect of the drug being approved in 2026.
Initiating the BKLA submission affirms management’s firm belief that the candidate product will gain regulatory approval. The research firm has echoed the company’s readiness for manufacturing and launch in non-muscle invasive bladder cancer. There are also potential expansion opportunities for Creto, which could enhance commercial opportunities for the CG oncology lead product.
In other news, CG Oncology announced on November 26 that Christina Rossi will join its Board of Directors, replacing Simone Song of ORI Capital, who stepped down after more than ten years with the company. Rossi has held senior roles at Sanofi Genzyme and Biogen and holds degrees from Duke and Harvard.
Her appointment comes as CG Oncology works toward a BLA submission for its investigational bladder cancer therapy, cretostimogene, which has been studied in more than 400 patients with non-muscle invasive bladder cancer. CEO Arthur Kuan noted that the team is preparing for a potential launch pending FDA approval, though the treatment is still under review.
CG Oncology, Inc. (NASDAQ:CGON) is a biopharmaceutical company focused on developing and commercializing novel, bladder-sparing immunotherapies for patients with urologic cancers, particularly bladder cancer.
5. Nuvalent, Inc. (NASDAQ:NUVL)
52 Week Range: $55.53 – $112.88
Current Share Price as of December 4: $108.82
Year to date Gain: 36.34%
Stock Upside Potential: 30.59%
Number of Hedge Fund Holders: 36
Nuvalent Inc. (NASDAQ:NUVL) is one of the best 52-week high stocks to buy right now. On November 24, Truist Securities initiated coverage of Nuvalent Inc. (NASDAQ:NUVL) with a Buy rating and a $140 price target, impressed by the company’s prospects in lung cancer drug development.
The company’s cancer drugs Nela and Zide are on the cusp of being approved for commercialization in lung cancer treatment. The US Food and Drug Administration has accepted the company’s New Drug Application for Zide.
The research firm expects the company’s Zide treatment to capture significant market share in TKI-pretreated ROS1-positive NSCLC. The drug could secure regulatory approval by the second quarter of next year following Breakthrough Therapy Designation.
On the other hand, on November 24, Nuvalent Inc. completed a public offering of 4.95 million Class A shares at $101 each, raising about $500 million in gross proceeds before fees and expenses, the company announced.
On November 20, Jefferies lifted its price target on Nuvalent to $164 from $137 and kept its Buy rating after reviewing topline results from the ALKove-1 trial of neladalkib in previously treated NSCLC. The drug showed a 17.6-month median response duration, more than twice the current standard, with a clean safety profile, no neurotoxicity, and solid activity in CNS disease and key ALK mutation groups. Jefferies views it as a strong contender for second- and third-line therapy. Nuvalent is pushing for a broad label and expects the drug’s durability to help it capture a sizeable share of an ALK-positive market that could top $5 billion.
Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company that creates precisely targeted therapies for cancer patients. Using its expertise in chemistry and structure-based drug design, the company develops innovative small-molecule drugs to overcome resistance, minimize side effects, and improve durability in patients with various cancers, particularly those affecting the lungs.
4. Wheaton Precious Metals Corp. (NYSE:WPM)
52 Week Range: $55.47 – $114.36
Current Share Price as of December 4: $109.02
Year to date Gain: 83.85%
Stock Upside Potential: 20.40%
Number of Hedge Fund Holders: 38
Wheaton Precious Metals Corp (NYSE:WPM) is one of the best 52-week high stocks to buy right now. On November 26, the company increased its proven and probable gold reserves by 0.19 million ounces. The company entered into a gold stream agreement with Carcetti Capital Corporation. While the agreement is poised to support Carcetti Capital’s acquisition of the Hemlo Mine from Barrick Gold, it will allow the company to gain access to a reliable stream of gold production.
Wheaton is to purchase 10.13% of payable gold until 135,750 ounces are delivered. The percentage is to drop to 6.75% until an additional 117,998 pounds is delivered, and then to 4.50% for the life of the mine. Under the gold stream agreement, the company is to access 15 ounces of gold annually for the first 10 years, and thereafter access over 13,000 ounces per year.
Earlier on November 24, BofA nudged its price target on Wheaton Precious Metals down to $132 from $133 but kept its Buy rating. The slight change comes after updated Metals & Mining forecasts, with analysts noting that weaker commodity demand from China is weighing on the sector, even as trends in the U.S. and Europe show signs of improvement.
Wheaton Precious Metals Corp. (NYSE:WPM) is a precious metals streaming company that enters into agreements with mining companies to purchase a portion of their future production, such as gold, silver, platinum, palladium, and cobalt. In exchange for an upfront payment and a per-ounce cost, Wheaton receives a percentage of the mine’s precious metals.
3. Centessa Pharmaceuticals plc (NASDAQ:CNTA)
52 Week Range: $9.60 – $29.99
Current Share Price as of December 4: $29.69
Year to date Gain: 65.60%
Stock Upside Potential: 29.17%
Number of Hedge Fund Holders: 40
Centessa Pharmaceuticals plc (NASDAQ:CNTA) is one of the best 52-week high stocks to buy right now. On December 1, B. Riley boosted its price target on Centessa Pharmaceuticals plc (NASDAQ:CNTA) to $42 from $33 and reiterated its Buy rating after impressive Phase 2 data for ORX750.
The CRYSTAL-1 study showed strong wake-promoting effects at much lower doses than competing drugs, with meaningful benefits in narcolepsy type 2 and idiopathic hypersomnia: including an 87% drop in cataplexy episodes, and a clean safety profile. Analysts pointed to Centessa’s potential lead over other developers, rising investor support, and a growing market for orexin-based therapies, especially as the Alkermes-Avadel merger highlights momentum in the space ahead of expected launches starting in 2026.
Previously on November 18, analysts at Guggenheim lifted their price target of the stock to $43 from $28 while reiterating a Buy rating. The price target hike follows the company’s topline results from its ORX750 CRYSTAL-1 Phase 2a study. According to Guggenheim, Centessa remains well-positioned to advance ORX750 in pivotal trials following an equity financing that raised $619 million in pro forma cash. Development of the candidate drug could expand its addressable market by targeting neurodegenerative and neuropsychiatric disorders.
Centessa Pharmaceuticals plc (NASDAQ:CNTA) is a pharmaceutical company that discovers and develops transformational medicines for patients with high unmet needs. Its key programs include a hemophilia program, an orexin agonist program for sleep-wake disorders like narcolepsy, and an immune-oncology program.
2. nVent Electric plc (NYSE:NVT)
52 Week Range: $41.71 – $117.52
Current Share Price as of December 4: $107.10
Year to date Gain: 55.61%
Stock Upside Potential: 20.86%
Number of Hedge Fund Holders: 61
nVent Electric plc (NYSE:NVT) is one of the best 52-week high stocks to buy right now. On November 20, UBS initiated coverage of the stock with a Buy rating and a $128 price target. The research firm remains optimistic about the company’s prospects, driven by improving demand in the data center and power infrastructure segments. The two segments account for about 40% of the company’s sales and act as drivers of a positive outlook.
Consequently, UBS expects the company to achieve annual organic sales growth of more than 10% through 2027. The firm also expects sales and earnings per share to exceed consensus estimates by about 300 basis points.
The company is staring at a growing data center pipeline and increasing electricity demand. Consequently, on November 17, it confirmed the unveiling of a new liquid-cooling solution targeting AI data centers. nVent rolled out a refreshed lineup of liquid-cooling hardware for data centers, including upgraded coolant distribution units, cooling manifolds, new racks, and next-gen power distribution units built on a shared control platform.
The portfolio features modular row- and rack-level CDUs with both AC and DC options. nVent is also working with Siemens on a reference architecture for hyperscale AI cooling and contributing a Google-aligned CDU design to Project Deschutes. The company has broadened its service offerings as well, adding installation, start-up support, maintenance, and repair for liquid-cooling systems.
nVent Electric plc (NYSE:NVT) designs, manufactures, markets, installs, and services high-performance electrical connection and protection solutions to help make systems safer and more secure. Its products are used in various applications, such as data centers, industrial facilities, and buildings.
1. Carpenter Technology Corporation (NYSE:CRS)
52 Week Range: $138.61 – $342.11
Current Share Price as of December 4: $308.57
Year to date Gain: 79.34%
Stock Upside Potential: 23.81%
Number of Hedge Fund Holders: 67
Carpenter Technology Corporation (NYSE:CRS) is one of the best 52-week high stocks to buy right now. Carpenter Technology Corporation (NYSE:CRS) commands a consensus buy rating from 6 Wall Street analysts, with 6 Buy ratings. The average price target for the stock is $389.67, implying 23.81% upside from the current level of $314.74.
On November 20, the company closed a $700 million offering of 5.625% senior notes due 2034. The public offering bolstered the company’s financial position by enabling it to redeem its 6.375% senior notes due 2028 and 7.625% notes due 2030.
The $700 million offering comes on the heels of KeyBanc upgrading Carpenter Technology to an Overweight with a $380 price target. The positive stance also comes amid expectations that strong pricing, favorable product mix, and effective cost control will drive the company’s performance next year.
The research firm has noted three 5-year-long-term agreements at 10% higher prices, along with ongoing strength in transactional pricing, which are expected to drive financial performance. Consequently, operating income is expected to exceed expectations in 2026 and 2027 as Boeing 737/MAX production resumes.
Carpenter Technology Corporation (NYSE:CRS) is a global provider of high-performance specialty alloys and advanced materials for critical applications. The company manufactures premium specialty alloys, including nickel- and cobalt-based superalloys and stainless steels, and offers process solutions such as additive manufacturing and custom-engineered products.
While we acknowledge the potential of CRS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Cybersecurity Stocks to Buy Under $50 and 13 Best Augmented Reality Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
